Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Decrease in Short Interest

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) saw a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 8,700,000 shares, a drop of 15.7% from the June 30th total of 10,320,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is currently 6.8 days.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 57.7% during the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after purchasing an additional 3,488,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 39.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock valued at $18,416,000 after purchasing an additional 576,120 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $2,089,000. GSA Capital Partners LLP lifted its holdings in shares of Aurinia Pharmaceuticals by 196.1% during the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after purchasing an additional 231,260 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Aurinia Pharmaceuticals by 51.7% during the first quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock valued at $1,552,000 after purchasing an additional 105,100 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Stock Down 0.4 %

Aurinia Pharmaceuticals stock traded down $0.02 during trading hours on Tuesday, hitting $5.66. 814,658 shares of the stock traded hands, compared to its average volume of 1,763,006. The firm’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $5.80. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The company has a market cap of $809.49 million, a PE ratio of -13.19 and a beta of 1.44. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $12.38.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.14. The business had revenue of $50.30 million for the quarter, compared to analysts’ expectations of $46.30 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. On average, research analysts forecast that Aurinia Pharmaceuticals will post 0.15 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.